Mason & Associates Inc Has $216,000 Stock Position in Edwards Lifesciences Corporation (NYSE:EW)

Mason & Associates Inc decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 57.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,982 shares of the medical research company's stock after selling 4,080 shares during the quarter. Mason & Associates Inc's holdings in Edwards Lifesciences were worth $216,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Alyeska Investment Group L.P. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $49,038,000. Simplify Asset Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth approximately $5,979,000. Truist Financial Corp boosted its stake in Edwards Lifesciences by 19.3% during the 4th quarter. Truist Financial Corp now owns 41,340 shares of the medical research company's stock valued at $3,060,000 after purchasing an additional 6,676 shares in the last quarter. Assetmark Inc. boosted its stake in Edwards Lifesciences by 786.9% during the 4th quarter. Assetmark Inc. now owns 1,082 shares of the medical research company's stock valued at $80,000 after purchasing an additional 960 shares in the last quarter. Finally, Advanced Portfolio Management LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at $328,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 5,980 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the transaction, the chief executive officer now directly owns 58,284 shares of the company's stock, valued at approximately $4,366,054.44. This represents a 9.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the transaction, the vice president now owns 47,206 shares of the company's stock, valued at approximately $3,295,450.86. This represents a 16.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,898 shares of company stock worth $3,796,154 in the last quarter. Insiders own 0.34% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $1.51 during trading on Tuesday, reaching $73.31. The stock had a trading volume of 3,002,914 shares, compared to its average volume of 5,235,880. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The business's 50-day moving average price is $74.70 and its 200 day moving average price is $72.96. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The stock has a market capitalization of $43.00 billion, a PE ratio of 10.47, a P/E/G ratio of 3.77 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the company posted $0.66 earnings per share. Edwards Lifesciences's quarterly revenue was up 6.2% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Truist Financial reduced their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Piper Sandler increased their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Robert W. Baird raised their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and an average target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.